Journal ArticleDOI
Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches
Gonzalo Sapisochin,Jordi Bruix +1 more
Reads0
Chats0
TLDR
A comprehensive overview of the outcomes after liver transplantation for HCC, focusing on tumour recurrence in terms of surveillance, prevention and treatment is provided.Abstract:
Liver transplantation for hepatocellular carcinoma (HCC) is the best treatment option for patients with early-stage tumours and accounts for ∼20-40% of all liver transplantations performed at most centres worldwide. The Milan criteria are the most common criteria to select patients with HCC for transplantation but they can be seen as too restrictive. Several proposals have been made for a moderate expansion of the criteria, which result in good outcomes but with an increase in the risk of tumour recurrence. In this Review, we provide a comprehensive overview of the outcomes after liver transplantation for HCC, focusing on tumour recurrence in terms of surveillance, prevention and treatment. Additionally, novel surgical techniques have been developed to increase the available pool of organs for liver transplantation (such as living donor liver transplantation, donation after circulatory death and split livers), but the effect of these techniques on patients with HCC is still under debate. Thus, we will describe these techniques and expose the benefits and disadvantages of each surgical approach. Finally, we will comment on the limitations of the current priority policies for liver transplantation and the need to further refine them to better serve the population.read more
Citations
More filters
Journal ArticleDOI
Patterns and Predictors of Mortality After Waitlist Dropout of Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation.
Andre Gorgen,Roizar Rosales,Erin Sadler,R. Beecroft,Jennifer J. Knox,Laura A. Dawson,Anand Ghanekar,David R. Grant,Paul D. Greig,Gonzalo Sapisochin +9 more
TL;DR: The present study identifies the patterns of waitlist dropout in patients with HCC and provides evidence for the effectiveness of treatment strategies offered to HCC patients after dropout.
Journal ArticleDOI
Role of Liver-Mediated Tolerance in Nanoparticle-Based Tumor Therapy.
Maximiliano Luis Cacicedo,Carolina Medina-Montano,Leonard Kaps,Cinja Kappel,Stephan Gehring,Matthias Bros +5 more
TL;DR: This review aims to summarize current knowledge on the employment of nanocarriers for immunotherapeutic therapy of liver diseases and the overall role of liver NPCs in the context of nano-vaccination approaches and discusses strategies on how to address liver NPCs.
Journal ArticleDOI
Exosomal miR-4800-3p Aggravates the Progression of Hepatocellular Carcinoma via Regulating the Hippo Signaling Pathway by Targeting STK25
TL;DR: Exosomal miR-4800-3p could accelerate HCC development by regulating the Hippo signal by targeting STK25, which could be used as a new therapeutic target for HCC treatment.
Journal ArticleDOI
Accuracy of Milan, University of California San Francisco, and Up-To-7 Criteria in Predicting Tumor Recurrence Following Deceased-Donor Liver Transplant in Patients With Hepatocellular Carcinoma.
Behnam Saberi,Jacqueline Garonzik-Wang,Michelle Ma,Tokunbo Ajayi,Amy Kim,Harry Luu,Neha Jakhete,Aliaksei Pustavoitau,Robert A. Anders,Christos S. Georgiades,Ihab R. Kamel,Shane Ottmann,Benjamin Philosophe,Andrew M. Cameron,Ahmet Gurakar +14 more
TL;DR: Application of standard criteria has significantly improved prediction of hepatocellular carcinoma recurrence, and these criteria are inadequate, supporting the importance of other factors, including tumor biology.
Journal ArticleDOI
Immune checkpoint inhibitors in liver transplant recipients - a review of current literature
TL;DR: It is concluded that ICIs are valuable options in the peritransplant setting that have demonstrated promising efficacy based on case reports, and controlled clinical trials are needed to further investigate the conditions that may allow safe delivery of these therapies.
References
More filters
Journal ArticleDOI
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
Jacques Ferlay,Isabelle Soerjomataram,Rajesh Dikshit,Sultan Eser,Colin Mathers,Marise Souto Rebelo,Donald Maxwell Parkin,David Forman,Freddie Bray +8 more
TL;DR: The GLOBOCAN series of the International Agency for Research on Cancer (IARC) as mentioned in this paper provides estimates of the worldwide incidence and mortality from 27 major cancers and for all cancers combined for 2012.
Journal ArticleDOI
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Journal ArticleDOI
EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma
Peter R. Galle,Alejandro Forner,Josep M. Llovet,Vincenzo Mazzaferro,Fabio Piscaglia,Jean-Luc Raoul,Peter Schirmacher,Valérie Vilgrain +7 more
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
Journal ArticleDOI
Management of hepatocellular carcinoma: An update
Jordi Bruix,Morris Sherman +1 more
TL;DR: The American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) were updated in 2010 as discussed by the authors.
AASLD PRACTICE GUIDELINE Management of Hepatocellular Carcinoma: An Update
Jordi Bruix,Morris Sherman +1 more
TL;DR: Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated.
Related Papers (5)
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
Vincenzo Mazzaferro,Josep M. Llovet,Rosalba Miceli,Sherrie Bhoori,M. Schiavo,Luigi Mariani,Tiziana Camerini,Sasan Roayaie,Myron Schwartz,Gian Luca Grazi,René Adam,Peter Neuhaus,Mauro Salizzoni,Jordi Bruix,Alejandro Forner,Luciano De Carlis,Umberto Cillo,Andrew K. Burroughs,Roberto Troisi,Massimo Rossi,Giorgio Enrico Gerunda,Jan Lerut,Jacques Belghiti,Ilka de Fátima Santana Ferreira Boin,Jean Gugenheim,Fedja Rochling,Bart van Hoek,Pietro Majno +27 more
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more